TP53 and myelodysplastic syndrome: The analysis of the mOS in t-MDS patients showed that TP53-mutant patients had a significantly shorter survival than TP53-WT patients; among TP53-mutant MDS, neither the allelic status nor the bone marrow percentage provides a significant prognostic information; and 10% TP53 VAF is a clinically useful threshold to identify patients with poor survival [84].